Drug Approval | June 17, 2024
Alembic announces USFDA final approval for Icatibant injection
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Accelerating sustainability in Indian pharma industry
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Subscribe To Our Newsletter & Stay Updated
